KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies.

Joseph F Merola, Richard B Warren, Diamant Thaçi, Kenneth B Gordon, Emi Nishida, Bruce Strober, Curdin Conrad, Sarah Kavanagh, José Manuel López Pinto, Bengt Hoepken, Paolo Gisondi

Am J Clin Dermatol 26(6) 967-979

PMID40886218
PMCIDPMC12615549
DOI10.1007/s40257-025-00968-2
发表日期2025-08-31
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:AI 判定为 multi panel km。
摘要

摘要

BACKGROUND: Nail psoriasis can have a substantial negative impact on both the physical and emotional well-being of patients, and is a risk factor for psoriatic arthritis. Achieving complete clearance of nails in addition to skin is therefore an important treatment goal. OBJECTIVES: We aimed to evaluate concurrent complete skin and nail clearance in patients with moderate-to-severe plaque psoriasis treated with bimekizumab or active comparators. METHODS: Data were analyzed from the BE SURE and BE VIVID phase III trials, their open-label extension BE BRIGHT, and the BE RADIANT phase IIIb trial and its open-label extension. Included patients had baseline modified Nail Psoriasis Severity Index (mNAPSI) >0 and entered their respective open-label extension. Proportions of patients achieving complete skin (PASI 100; 100% improvement from baseline in Psoriasis Area and Severity Index) and nail (mNAPSI 0) clearance at the same time are reported for bimekizumab- and active comparator-treated patients during controlled trial periods, and in the long term for continuous bimekizumab-treated patients and those switching from comparators. Data are reported using modified non-responder imputation. RESULTS: At the end of comparator-controlled periods, 45.8% of bimekizumab (N = 151) versus 18.3% of adalimumab (N = 91) patients (BE SURE week 24), 51.1% of bimekizumab (N = 169) versus 26.5% of ustekinumab (N = 92) patients (BE VIVID week 52), and 63.3% of bimekizumab (N = 182) versus 36.1% of secukinumab (N = 155) patients (BE RADIANT week 48) achieved PASI 100 and mNAPSI 0. Following long-term treatment, 57.7% of adalimumab switchers/49.1% of continuous bimekizumab patients (BE SURE/BE BRIGHT year 4), 52.2% of ustekinumab switchers/48.3% of continuous bimekizumab patients (BE VIVID/BE BRIGHT year 4), and 51.9% of secukinumab switchers/57.4% of continuous bimekizumab patients (BE RADIANT year 3) achieved PASI 100 and mNAPSI 0. CONCLUSIONS: Numerically higher proportions of bimekizumab-treated patients achieved concurrent complete skin and nail clearance versus adalimumab, ustekinumab, and secukinumab. Clearance rates increased following switch to bimekizumab, and were sustained long-term in both switchers to bimekizumab and continuous bimekizumab-treated patients. [Graphical abstract available.] CLINICAL TRIAL REGISTRATION: NCT03412747, NCT03370133, NCT03598790, NCT03536884.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Complete skin clearance, nail clearance, and concurrent skin and nail clearance in comparator-controlled trial periods (modified non-responder imputation [mNRI]). a BE SURE week 24; b over 24 weeks in BE SURE; c BE VIVID week 52; d over 52 weeks in BE VIVID; e BE RADIANT week 48; f over 48 weeks in BE RADIANT. Bimekizumab (BKZ) Total represents all BKZ dose groups combined for patients in BE SURE and BE RADIANT. In BE VIVID, patients in the BKZ Total group received BKZ every 4 weeks (Q4W) only during the first year of treatment according to study design. Only patients with nail involvement (modified Nail Psoriasis Severity Index [mNAPSI] >0) at baseline who entered the open-label extensions were included in the analysis. ADA adalimumab, PASI 100 100% improvement from baseline in Psoriasis Area and Severity Index, Q8W every 8 weeks, SEC secukinumab, UST ustekinumab
非 KM Figure
Fig. 2Fig. 2 Long-term complete skin clearance, nail clearance, and concurrent skin and nail clearance, including among switchers to bimekizumab (BKZ) (modified non-responder imputation [mNRI], observed case [OC]). a BE SURE/BE BRIGHT week 200; b over 4 years in BE SURE/BE BRIGHT; c BE VIVID/BE BRIGHT week 196; d over 4 years in BE VIVID/BE BRIGHT; e BE RADIANT week 144; f over 3 years in BE RADIANT. Kinetic plots and bar charts report mNRI. The tables report OC. BKZ Total represents all bimekizumab dose groups combined. Only patients with nail involvement (modified Nail Psoriasis Severity Index [mNAPSI] >0) at baseline who entered the open-label extensions were included in the analysis. ADA adalimumab, PASI 100 100% improvement from baseline in the Psoriasis Area and Severity Index, Q4W every 4 weeks, Q8W every 8 weeks, SEC secukinumab, UST ustekinumab
非 KM Figure